Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.3.0.814
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Condensed Consolidated Statements Of Operations        
Revenues, net $ 118,192 $ 434,041 $ 851,437 $ 802,878
Operating expenses:        
Cost of implants and other costs 19,105 84,378 139,355 159,340
Selling, general and administrative $ 576,505 $ 500,695 1,279,898 $ 1,566,154
Termination of licensing agreement 3,639,694
Loss on settlement of sub-licenses 118,027
Depreciation and amortization $ 28,908 $ 33,803 96,197 $ 101,750
Total operating expenses 624,518 618,876 5,273,171 1,827,244
Loss from operations (506,326) (184,835) (4,421,734) (1,024,366)
Other income (expenses):        
Interest expense, net (164,742) (131,791) (327,396) (333,813)
(Loss) gain on change in fair value of derivative liability (26,403) (67,253) 77,765 237,697
Loss before income taxes $ (697,471) $ (383,879) $ (4,671,365) $ (1,120,482)
Income taxes
Net loss $ (697,471) $ (383,879) $ (4,671,365) $ (1,120,482)
Net loss per common share, basic and diluted $ 0.00 $ 0.00 $ (0.03) $ (0.01)
Weighted average number of common shares outstanding, basic and diluted 158,060,044 143,549,555 153,016,644 136,583,677